Cardiovascular Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Division of Cardiology, Department of Internal Medicine, Cincinnati VA Medical Center, Cincinnati, OH, 45220, USA.
Mol Cell Biochem. 2024 Mar;479(3):617-627. doi: 10.1007/s11010-023-04726-y. Epub 2023 May 3.
Hereditary hemochromatosis with the homozygous C282Y HFE mutation (HH-282H) is a genetic condition which causes iron overload (IO) and elevated reactive oxygen species (ROS) secondary to the IO. Interestingly, even after successful iron removal therapy, HH-282H subjects demonstrate chronically elevated ROS. Raised ROS are also associated with the development of multiple cardiovascular diseases and HH-282H subjects may be at risk to develop these complications. In this narrative review, we consider HH-282H subjects as a clinical model for assessing the contribution of elevated ROS to the development of cardiovascular diseases in subjects with fewer confounding clinical risk factors as compared to other disease conditions with high ROS. We identify HH-282H subjects as a potentially unique clinical model to assess the impact of chronically elevated ROS on the development of cardiovascular disease and to serve as a clinical model to detect effective interventions for anti-ROS therapy.
遗传性血色素沉着症伴纯合 C282Y HFE 突变(HH-282H)是一种遗传性疾病,可导致铁过载(IO)和活性氧(ROS)升高,继发于 IO。有趣的是,即使在成功进行铁去除治疗后,HH-282H 患者仍表现出慢性 ROS 升高。ROS 升高还与多种心血管疾病的发生有关,HH-282H 患者可能存在发生这些并发症的风险。在这篇叙述性综述中,我们将 HH-282H 患者视为一个临床模型,用于评估在其他 ROS 水平较高的疾病中,ROS 升高对心血管疾病发展的影响,同时 HH-282H 患者具有较少的混杂临床危险因素。我们将 HH-282H 患者确定为一个潜在的独特临床模型,用于评估慢性升高的 ROS 对心血管疾病发展的影响,并作为一种临床模型,用于检测抗 ROS 治疗的有效干预措施。